Antiplatelets, Anticoagulants What are the consequences Dr Jeremy Wright Cardiologist Hearts1st, Greenslopes Private Hospital.

Slides:



Advertisements
Similar presentations
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Advertisements

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Question: How should we manage periprocedural anticoagulation? Paper: Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures Todd.
Peri-Operative Management of Drug Eluting Stents
CLINICAL CASES.
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
Management of ST-elevation myocardial infarction according to European and American guidelines.
1 Update on antiplatelet and anticoagulant drugs: sticky stuff KFJ Ng May 2011.
Dalia Elfawy., MD Lecturer of Anesthesia and ICU Ain Shams University 2014 RAPID REVERSAL OF ANTICOAGULATION IN TRAUMA PATIENTS.
Dr David Scott Gastroenterologist Tamworth Base Hospital
GP Railway Workshops Heart Week Event Dr Chris Judkins MBBS MClinRes FRACP Interventional Cardiologist WA Cardiology Fiona Stanley.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Heart Care Centers of Illinois. Design –Single arm, open label, 13 U.S. centers –Patients with ST-segment elevation myocardial infarction (STEMI) Less.
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
Shujuan Cheng,MD; Hongbing Yan,MD Beijing Anzhen Hospital Capital Medical University, Beijing China Argatroban for Severe Thrombocytopnia after Primary.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Anticoagulation ACCP guidelines 2012
Unstable Angina and NSTEMIs: Management Principles Meira Louis Lisa Campfens.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Blood coagulation is a complex process that involves vasoconstriction, platelet clumping or aggregation, and a cascade of clotting factors produced in.
Anticoagulation Reversal May 11, Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Stent thrombosis, an old souvenir? January 15 th, h30.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Multivessel Coronary Artery Disease
Anticoagulants, Antiplatelets, and Thrombolytics
G UIDELINES FOR THE P ERI -P ROCEDURAL M ANAGEMENT OF A DULTS T AKING T ARGET S PECIFIC A NTICOAGULANTS (TSOAC S ): DABIGATRAN, RIVAROXABAN, APIXABAN,
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Mike Kolber BSc, MD, CCFP, MSc AAPCE Nov. 3, 2012.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Anticoagulation of Bioprosthetic Aortic Valves.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
Use of OCT in Determining Dual Antiplatelet Treatment Duration
Low Procedural Bleed Risk
Anticoagulants, Antiplatelets, and Thrombolytics
The management of anti-thrombotics in patients undergoing GI endoscopy
Anticoagulation after peripheral Vascular Intervention
Anesthes. 2013;118(6): doi: /ALN.0b013e318289bcba Figure Legend:
When should aspirin be dropped from triple therapy?
You can never be too Thin…. An Update on NOACs
Prof. 동석호 소화기내과 R2 윤수진.
Ortho Warfarin Dosing Protocol
Ischaemic Heart Disease Acute Coronary Syndrome
Tenecteplase (TNK-t-PA)‏
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Oral Anticoagulation and Preventing Stent Thrombosis
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Glenn N. Levine et al. JACC 2016;68:
Mandeep Singh, MD, MPH, Deepak L. Bhatt, MD, MPH, Gregg W
Antiplatelet Therapy and Secondary Prevention
Section F: Clinical guidelines
Peri-Endoscopic Management of Antithrombotic Agents
Factor Xa Inhibitors in PAD
Oral Anticoagulant Reversal Agents
Periprocedural Management of Patients on Anticoagulation
What oral antiplatelet therapy would you choose?
Nat. Rev. Cardiol. doi: /nrcardio
Roberta Rossini et al. JCIN 2018;11:
DuyKhanh P. Ceppa, MD, Ian J. Welsby, MBBS, Tracy Y. Wang, MD, Mark W
Management of Antithrombotic Medication in surgical patient
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Antiplatelets, Anticoagulants What are the consequences Dr Jeremy Wright Cardiologist Hearts1st, Greenslopes Private Hospital

Outline  2 clinical cases  Overview of haemostasis  Antiplatelet medications  Anticoagulant medications  Strategy for peri-procedural management

Case 1  86yo female  RCA stent 6 months ago  Hb 55, large colorectal cancer  Transfusion, staged anterior resection  Pre-op phone assessment advised stop Aspirin and Clopidogrel 1 week prior to surgery  Anterior resection performed  In recovery - chest pain and intermittent bradycardia

Case 1  Multiple VF arrests  Aspirated  Intubated  Angio showed stent thrombosis  IV heparin, eptifibatide  Prolonged stay in ICU  Discharged home 1 month later

Case 2  83 yo female  2 days post stent to LAD  Aspirin and Clopidogrel  Pleural effusion  Pleural tap requested to exclude empyema  Large haemothorax  Deceased despite resuscitation

Haemostasis

Antiplatelets Anticoagulants

Antiplatelet medications  Aspirin -Cartia, Astrix, etc  Clopidogrel -Plavix, Iscover  Prasugrel -Effient  Ticagrelor -Brilinta  Fish Oil, Chinese Herbs  GP IIb/IIIa inhibitors – Reopro, Aggrastat

Coronary Artery Stents  Three ‘Generations’ 1.) Bare Metal (BMS) 2.) Drug Eluting (DES) (first generation) 3.) Drug Eluting (DES) (second generation)  BMS require dual antiplatelet therapy for at least 1 month  DES require dual antiplatelet therapy for at least 6 months  Aspirin must continue

Anticoagulants  Older agents -Oral: Warfarin -Injection: Heparin, Clexane, Danaparoid, Fondaparinux  New oral agents -Dabigatran (Pradaxa) -Rivaroxaban (Xarelto) -Apixaban (Eliquis)  New injection agents -Lepirudin (Refludan) -Bivalirudin (Angiomax) -Desirudin (Revasc)

Time required for medications to wear off  Antiplatelets: 7 days  Warfarin: 5 days  Injections: 6-24 hours  New oral agents -Dabigatran (Pradaxa) 2 days if eGFR>50, otherwise 5 days -Rivaroxaban (Xarelto) 1-2 days -Apixaban (Eliquis) 1-2 days

General Principles  Assess thromboembolic risk of stopping medication -Why taking the medication -How long ? -Previous bleeding problems  Assess bleeding risk associated with the procedure  Ultimate responsibility lies with the Dr performing the procedure, assisted by the referring Dr  Bridging medications may be required in some circumstances

Confused?  CSANZ 2009  Warfarin for prosthetic valves ?

Confused?  Society of Interventional Radiology Consensus Guidelines  J Vasc Interv Radiol 2009; 20:S240-S249

Take home messages  Critical to find out what the patient is taking – oral, SC, IV  There are many new medications -If not sure, look it up or ask  These decisions can be complex  Communication is the key